PMID- 26261659
OWN - NLM
STAT- MEDLINE
DCOM- 20160516
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 6
DP  - 2015
TI  - Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell 
      lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
PG  - 7494-8
AB  - T(12;14)(p13;q32) is a rare recurrent chromosomal translocation, which has only 
      been identified in a small subgroup of mantle cell lymphoma (MCL) without typical 
      t(11;14)(q13;q32). This rearrangement causes aberrant over-expression of cyclin 
      D2 (CCND2), which disrupts the normal cell cycle. Here we report a subtle case of 
      MCL with t(12;14)(p13;q32) that was initially misdiagnosed as ultra-high risk 
      chronic lymphocytic leukemia (CLL). A 60-year-old male patient presented with 
      obvious leukocytosis and progressive weakness. Morphology of peripheral blood and 
      immunophenotyping by flow cytometry pointed to a diagnosis of chronic lymphocytic 
      leukemia. Fluorescence in situ hybridization (FISH) using IGH-CCND1 probe was 
      negative for CCND1 abnormality, but demonstrated IGH breakapart signals. The 
      initial diagnosis of CLL was established and the patient was treated with six 
      courses of immunochemotherpy with fludarabine, cyclophosphamide and rituximab 
      (FCR). Complete remission (CR) was achieved at the end of treatment, but disease 
      relapsed quickly. The patient was transferred to our hospital, flow cytometry 
      using additional markers showed that the clonal cells were CD200+(dim), 
      CD148+(strong), and chromosome analysis revealed a complex karyotype, 47, XY, 
      t(12;14)(p13;q32), +12, del(9p21), which indicated over-expression of CCND2, and 
      immunostaining showed strong positivity of SOX11 further confirming the 
      characteristics of CCND1-negtive MCL. The final diagnosis was revised to rare 
      subtype of MCL with CCND2 translocation and intensive regimens were employed. 
      This confusable MCL case illustrates the importance of cytogenetic analysis and 
      clinicopathologic diagnosis of this rare category of MCL.
FAU - Miao, Yi
AU  - Miao Y
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Fan, Lei
AU  - Fan L
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Qiu, Hairong
AU  - Qiu H
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Wu, Yujie
AU  - Wu Y
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Chen, Yaoyu
AU  - Chen Y
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
FAU - Li, Jianyong
AU  - Li J
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital Nanjing 210029, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150601
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - Bone Marrow Examination
MH  - *Chromosomes, Human, Pair 12
MH  - *Chromosomes, Human, Pair 14
MH  - Cyclin D1/*genetics
MH  - Diagnosis, Differential
MH  - Diagnostic Errors
MH  - Disease Progression
MH  - Fatal Outcome
MH  - *Genes, Immunoglobulin Heavy Chain
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/immunology/pathology
MH  - Lymphoma, Mantle-Cell/chemistry/drug therapy/*genetics/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Time Factors
MH  - *Translocation, Genetic
MH  - Treatment Outcome
PMC - PMC4525993
OTO - NOTNLM
OT  - CD148
OT  - SOX11
OT  - cyclin D2
OT  - mantle cell lymphoma
OT  - t(12;14)
EDAT- 2015/08/12 06:00
MHDA- 2016/05/18 06:00
PMCR- 2015/06/01
CRDT- 2015/08/12 06:00
PHST- 2015/03/17 00:00 [received]
PHST- 2015/05/17 00:00 [accepted]
PHST- 2015/08/12 06:00 [entrez]
PHST- 2015/08/12 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Jun 1;8(6):7494-8. eCollection 2015.